Journal of Antimicrobial Chemotherapy (1999) 44, 679-688
© 1999 The British Society for Antimicrobial Chemotherapy
Brief report |
The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone
Department of Medical Microbiology, City Hospital NHS Trust, Birmingham, UK
The in-vitro activity of gemifloxacin, a new fluoroquinolone, against a wide range (c. 700) of recent clinical isolates, was compared with that of three other fluoroquinolones and other relevant agents. Gemifloxacin inhibited 90% of the Enterobacteriaceae strains at 0.5 mg/L or less, exceptions being Serratia spp. (MIC90 1 mg/L) and strains possessing a putative mechanism of resistance to fluoroquinolones. Ninety per cent of Pseudomonas aeruginosa were inhibited by 4 mg/L. Gemifloxacin had good activity against respiratory pathogens, with 90% of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis being inhibited by 0.06 mg/L or less. Staphylococcus aureus (MSSA) were highly susceptible (MIC90 0.06 mg/L) but MRSA less susceptible (MIC90 8 mg/L) to gemifloxacin. Enterococcus spp. were markedly more susceptible to the study agent than to ciprofloxacin. Gemifloxacin showed good activity against Bacteroides fragilis (MIC90 0.5 mg/L) and anaerobic cocci. A tentative in-vitro breakpoint of 0.5 mg/L was studied using a 1 µg disc content for all genera except Pseudomonas where a 5 µg disc content was employed. The false sensitivity reporting rate was 0.5% and false resistance rate was 6.0%, which was considered acceptable. In conclusion, gemifloxacin is a highly active fluoroquinolone that should prove clinically useful in the treatment of a wide range of infections. Susceptibility testing criteria have been developed that should prove robust in a clinical laboratory.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. N. Leonard, G. W. Kaatz, L. R. Rucker, and M. J. Rybak Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus J. Antimicrob. Chemother., December 1, 2008; 62(6): 1305 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Azoulay-Dupuis, J. P. Bedos, J. Mohler, P. Moine, C. Cherbuliez, G. Peytavin, B. Fantin, and T. Kohler Activity of Gemifloxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1046 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Pereyre, H. Renaudin, C. Bebear, and C. M. Bebear In Vitro Activities of the Newer Quinolones Garenoxacin, Gatifloxacin, and Gemifloxacin against Human Mycoplasmas Antimicrob. Agents Chemother., August 1, 2004; 48(8): 3165 - 3168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Ling, A. W. Lam, E. W. Chan, and A. F. Cheng What have we learnt from community-acquired infections in Hong Kong? J. Antimicrob. Chemother., April 1, 2003; 51(4): 895 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Boswell, J. M. Andrews, G. Jevons, and R. Wise Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance J. Antimicrob. Chemother., October 1, 2002; 50(4): 495 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Perez-Trallero, C. Garcia-Rey, A. M. Martin-Sanchez, L. Aguilar, J. Garcia-de-Lomas, and J. Ruiz Activities of Six Different Quinolones against Clinical Respiratory Isolates of Streptococcus pneumoniae with Reduced Susceptibility to Ciprofloxacin in Spain Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2665 - 2667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wise, J. M. Andrews, and J. Ashby In Vitro Activities of Peptide Deformylase Inhibitors against Gram-Positive Pathogens Antimicrob. Agents Chemother., April 1, 2002; 46(4): 1117 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ruiz, A. Jurado, E. Garcia-Mendez, F. Marco, L. Aguilar, M. T. Jimenez de Anta, and J. Vila Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones J. Antimicrob. Chemother., October 1, 2001; 48(4): 545 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. MacGowan, C. A. Rogers, H. A. Holt, M. Wootton, and K. E. Bowker Pharmacodynamics of Gemifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model of Infection Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2916 - 2921. [Abstract] [Full Text]
|
|
|
|
|
|
L. Martinez-Martinez, P. Joyanes, A. I. Suarez, and E. J. Perea Activities of Gemifloxacin and Five Other Antimicrobial Agents against Listeria monocytogenes and Coryneform Bacteria Isolated from Clinical Samples Antimicrob. Agents Chemother., August 1, 2001; 45(8): 2390 - 2392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kleinkauf, G. Ackermann, R. Schaumann, and A. C. Rodloff Comparative In Vitro Activities of Gemifloxacin, Other Quinolones, and Nonquinolone Antimicrobials against Obligately Anaerobic Bacteria Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1896 - 1899. [Abstract] [Full Text]
|
|
|
|
|
|
T. Gee, J. M. Andrews, J. P. Ashby, G. Marshall, and R. Wise Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose J. Antimicrob. Chemother., April 1, 2001; 47(4): 431 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Hoban, S. K. Bouchillon, J. A. Karlowsky, J. L. Johnson, D. L. Butler, L. A. Miller, J. A. Poupard, and The Gemifloxacin Surveillance Study Research Group A Comparative In Vitro Surveillance Study of Gemifloxacin Activities against 2,632 Recent Streptococcus pneumoniae Isolates from across Europe, North America, and South America Antimicrob. Agents Chemother., November 1, 2000; 44(11): 3008 - 3011. [Abstract] [Full Text]
|
|
|
|
|
|
V. J. Heaton, J. E. Ambler, and L. M. Fisher Potent Antipneumococcal Activity of Gemifloxacin Is Associated with Dual Targeting of Gyrase and Topoisomerase IV, an In Vivo Target Preference for Gyrase, and Enhanced Stabilization of Cleavable Complexes In Vitro Antimicrob. Agents Chemother., November 1, 2000; 44(11): 3112 - 3117. [Abstract] [Full Text]
|
|